Analgesics Market
Analgesic Sales Rise Due to the Adoption of Pain Management Therapeutics. FMI Tracks the Demand across 30+ Countries.
Analgesics Market by Drug Class, Indication, Route of Administration, Distribution Channel & Region – Forecast 2023–2033
Analgesics Market Outlook- 2023-2033
The market share of analgesics is predicted to grow from US$ 87.3 Bn in 2023 to over US$ 132.0 Bn by 2033. There is an increase in the number of patients suffering from acute, chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis or infectious diseases such as gastrointestinal, respiratory, and neurological ailments. The rise of these diseases increases the demand for painkillers. This is expected to further drive the market share of analgesics and register a CAGR of 4.2% between 2023 and 2033
Analgesics sales will be adversely impacted by the growing population of older people because they are more susceptible to chronic and lifestyle-related diseases. Additionally, the US Food and Drug Administration's (USFDA) approval of a strong pipeline of effective drugs is expected to support analgesic market growth.
A large portion of the increase in the geriatric population is responsible for the increased demand for analgesics. By 2050, there are expected to be more than 2100 million people over the age of 60, making up around 21% of the global population. Additionally, key manufacturers are present in the market to manufacture and distribute analgesic drugs, and consumer expenditure on healthcare is increasing.
As the number of clinical trials to evaluate the safety and efficacy of a wide range of therapeutic drugs increases, the analgesics market will continue to grow. Furthermore, analgesics market trends are primarily driven by the increasing number of elderly people, cardiovascular diseases, cancer, and arthritis.
Additionally, the aging population faces frequent pain and aches, which increases market demand. The analgesics market forecast period will be characterized by remunerative opportunities for the expansion of the global analgesic market. This is a result of technological development in the pharmaceutical industry to manufacture advanced analgesic drugs.
Further, private and government funding for pharmaceutical manufacturing segments and R&D activities for advancing analgesic products have boosted the growth of the analgesics industry. Growth is driven by government and private initiatives to develop the pharmaceutical and analgesic industries.
Generally, opioids can be obtained through prescriptions globally. However, people are prone to obtaining fake prescriptions and obtaining these drugs easily, which is a global problem and a factor that constrains market growth.
|
Attributes |
Details |
|
Analgesics Market Value (2023) |
US$ 87.3 Bn |
|
Analgesics Market Expected Value (2033) |
US$ 132.0 Bn |
|
Analgesics Market Projected CAGR (2023-2033) |
4.2% |
Let us know your requirement to get
100% FREE customization
Global Analgesics Market Historical Analysis (2017 to 2022) Vs. Forecast Outlook (2023 to 2033)
The global analgesics market expanded at 5.6% CAGR over the past 5 years. Analgesics is defined as a term that encompasses a class of drugs designed to provide pain relief without causing a loss of consciousness. Opioid analgesics have been adopted worldwide and are recognized as the most effective and widely used drugs for the treatment of severe pain.
The global demand for analgesics arises from the goal of improving healthcare outcomes. This includes pain management, which requires a multidisciplinary approach to administer. Apart from this, the formulation of opioid analgesics with abuse-deterrent properties by manufacturers has created a high demand for analgesics over the globe.
- According to the WHO, there are only about 14% of people over the globe receive palliative care. Additionally, each year, the global estimation of people in need of palliative care is about 40 million. The low and middle-income economies carry over 78% of that population metric.
The global rise in the prevalence of neuropathic and chronic pain, as well as advancements in pain management measures, are key factors pushing global analgesics sales. The market is expected to expand at a CAGR of close to 4.2% over the forthcoming decade.
- Short Term (2022 to 2025): There is an expectation that the pandemic will increase demand for analgesics on the global market. The pandemic has stressed healthcare systems around the world and heightened the need for advanced hospitals. A rise in the spread of infection increased the demand for analgesic drugs such as paracetamol and drove the market to grow.
- Medium Term (2025 to 2028): The presence of effective treatment options, large-scale investment in medical research and development, and the rising adoption of analgesics among different age groups are also expected to drive the growth of the analgesics market.
- Long Term (2028 to 2033): New pain reliever drugs are expected to create significant growth opportunities for market players due to the increasing demand for personalized medicine.
| Historical CAGR (2016-2022) | 5.6% |
| Historical Market Value | US$ 82.9 Bn |
| Forecast CAGR | 4.2% |
Comparative Analysis of Adjacent Analgesics Markets
Analgesics Market:
|
Differentiating Aspects |
Analgesics Market |
|
CAGR (2023-2033) |
4.2% |
|
Market Valuation in 2023 |
US$ 87.3 Bn |
|
Projected Market Value in 2033 |
US$ 132.0 Bn |
|
Growth Factors |
Rising prevalence of healthcare infrastructure. |
|
Opportunities |
An increasing number of strategic collaborations and R&D activities. |
|
Key Trends |
Several government initiatives to spread awareness and sedentary lifestyles of people. |
Topical Pain Relief Market:
|
Differentiating Aspects |
Topical Pain Relief Market |
|
CAGR (2023-2033) |
5.1% |
|
Market Valuation in 2023 |
US$ 10.86 Bn |
|
Projected Market Value in 2033 |
US$ 18.023 Bn |
|
Growth Factors |
Increasing prevalence of osteoarthritis and other bone-related conditions, such as diabetic neuropathy. |
|
Opportunities |
Online platforms for topical therapeutics are expected to offer lucrative growth prospects. |
|
Key Trends |
Growth in the topical pain relief industry is being driven by a growing demand for non-opioids. |
Opioid Analgesics Market:
|
Differentiating Aspects |
Opioid Analgesics Market |
|
CAGR (2023-2033) |
5.4% |
|
Market Valuation in 2023 |
US$ 43.32 Bn |
|
Projected Market Value in 2033 |
US$ 73.3 Bn |
|
Growth Factors |
The rising prevalence of orthopaedic diseases, cancer, and chronic pain among the geriatric population. |
|
Opportunities |
Market manufacturers in the opioid drugs market are expected to commercialize opioid-tolerant drugs. |
|
Key Trends |
The opioid analgesics market is being fueled by rising healthcare costs and rising disposable income. |
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystMajor Factors Driving Analgesics Market
- Rising Prevalence of Chronic Diseases
Analgesic medications treat and relieve persistent or severe pain caused by a variety of medical problems. Long-term diseases fuel industry growth. Cardiovascular disorders, in particular, contribute to industry growth. Over 20% of Americans suffer from chronic pain. This is according to a report provided by the National Center for Health Statistics of the US Centers for Disease Control and Prevention in 2019. A rise in the prevalence of diseases such as cancer has also increased the number of people suffering from chronic pain.
- Increasing Investment in Healthcare Infrastructure
Healthcare expenditure, which helps to improve healthcare infrastructure, is another significant factor influencing the growth rate of the analgesics market. Further, various government organizations are striving to improve healthcare infrastructure by increasing funding, which will further affect market dynamics.
Moreover, the surge in the geriatric population and government initiatives to spread awareness will result in the expansion of the analgesics market. Additionally, the increase in disposable income and the sedentary lifestyle of people will boost the market growth.
Major Restrain Faced by Analgesics Market
- The Severity of Abusive Opioids & their Misuse
Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased their overall sales in the global analgesics market. According to the International Association for the Study of Pain (IASP), around 20–30% of opioids prescribed for chronic pain are being misused. Besides this, as per the association, up to 10% of the total opioid consumers are addicted to it.
The consumption of opioids per capita is low in Asian countries. As per the Global Opioids Policy Initiative (GOPI), factors responsible for the low usage of opioids in Asia and Africa are requirements of the complete cost of payment by the patient, registration of patient receiving an opioid prescription, unavailability of some opioid formulations and physician requirement to receive permission for opioid prescriptions. These factors might restrain the analgesics market growth in the region.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Key Opportunities for Analgesics Market
Many people find a certain dose of opioids to be ineffective in cases of severe pain. These patients need to take higher doses of drugs to subdue the pain, which eventually makes them opioid-tolerant, and in some cases, addicted. Hence, commercializing opioid-tolerant drugs is expected to be one of the main opportunities for players in the opioid drugs market. This will also help in reducing the side effects related to or caused by increased consumption of opioid drugs.
For pain management, opioids are largely used in North America and Western Europe but due to increasing usage of opioids for non-medical purposes, the governing bodies of respective countries are encouraging doctors to prescribe non-opioid analgesics, which provides an opportunity for the companies to introduce novel non-opioid drugs.
The introduction of non-opioid analgesics in markets such as Asia and Africa, where opioids, as well as non-opioid drugs with novel drug delivery systems, are not widely available for pain management, creates opportunities for the growth of the analgesics market.
The rising cases of opioid dependency and the abuse of painkillers have led to the development of different abuse-deterrent technologies. Expansion of manufacturing facilities across regions with scarce novel drug delivery systems will create an opportunity for sales growth in the analgesics market over the forecast period.
Major Challenges Faced by Analgesics Market
- The Use of Biologics is on the Rise
Biotechnology is limiting the growth of the analgesics market due to the growth of biologics for treating inflammatory and neuropathic pain. Biologicals are medications that are made from living organisms, including humans, animals, and microorganisms.
These medications contain proteins, modified human hormones, or cells that produce compounds that suppress or stimulate immune system components. Biologics are more effective than analgesics, which only provide effective pain relief for 50% of patients, and are therefore used more often today.
Analgesics market growth will be hindered by the high cost of drug development and distribution. Furthermore, the lack of healthcare infrastructure and lack of skilled professionals will pose challenges. Furthermore, government regulations and a lack of awareness will further impede the market’s growth rate.
Analgesics Market Category-Wise Insights
Which Analgesics Drug Class is Witnessing Maximum Demand?
By drug type, the demand for opioids is projected to increase at a CAGR of 4.8% during the forecast period. The high demand for this drug class is because of the rising burden of chronic pain and inflammation globally.
By Indication, Which Segment is leading the Analgesics Market?
Surgical pain holds a revenue share of 53.3% in 2023 and is projected to continue accounting for over half of sales in the market by 2033. This trend in market revenue share is associated with the increasing adoption of surgical procedures worldwide.
Which is the Preferred Distribution Channel for Analgesics Sales?
Based on distribution channels, hospital pharmacies led the analgesics market with more than 30.1% market share with a CAGR of 5.4% in 2023. The controlled sales of opioid analgesics contribute to a higher market share for hospital pharmacies.
| Segment | Top Drug Class |
| Attributes | Opioids |
| Historical CAGR | 5.7% |
| Forecasted CAGR | 4.8% |
| Segment | Top Distribution Channel |
| Attributes | Hospital Pharmacies |
| Historical CAGR | 6.6% |
| Forecasted CAGR | 5.4% |
Regions Leading in Analgesics Market: Country-Wise Analysis
| Regions | North America |
| Countries | United States |
| Historical CAGR | 5.1% |
| CAGR | 3.5% |
| Market Value (2022) | US$ 14.6 Bn |
| Market Value (2033) | US$ 50.6 Bn |
| Regions | Europe |
| Countries | United Kingdom |
| Historical CAGR | 5.4% |
| CAGR | 4.2% |
| Market Value (2022) | US$ 1.9 Bn |
| Market Value (2033) | US$ 5.5 Bn |
| Regions | Asia Pacific |
| Countries | China, Japan, India |
| Historical CAGR | 7.1%, 5%, 7.3% |
| CAGR | 5.7%, 4%, 6.4% |
| Market Value (2022) | US$ 4.7 Bn, US$ 1.7 Bn, US$ 1.3 Bn |
| Market Value (2033) | US$ 11.2 Bn, US$ 5.2 Bn, US$ 2.7 Bn |
What Makes the U.S. Analgesics Market Dominant in North America?
The U.S. dominates the North American analgesics market with a total share of 86.5% in 2022 and is projected to continue exhibiting high demand through the course of the forecast period.
As per the documentation in 2016 by the National Health Institute, over 20% of adults in the U.S. suffer from chronic pain and 8% had high-impact chronic pain. This factor has leveraged analgesics demand in the country.
The Canadian Pain Task Force (CPTF) by the government of Canada was established in 2019 to deliver advice to guide the federal government towards better-quality methods for the prevention and management of chronic pain, a diagnosis affecting nearly 8 million people living in Canada. These initiatives will continue favoring the expansion of the analgesics market in North America.
Why is Germany’s Analgesics Market Considered Lucrative within Europe?
Germany dominates the Europe analgesics market, with a share of 23.2%. Germany’s dominance is supported by the rising number of over-the-counter (OTC) pharmacies in the country.
The trend of self-medication in Germany is highly prevalent. Sales of non-prescription analgesics via OTC pharmacies in Germany have been characterized as one of the main drivers of sales of analgesics in the country.
What Makes China Analgesics Market Highly Attractive?
China holds a 54.3% share of the East Asia market and is projected to expand at a CAGR of over 5.7%. According to research published in the Journal of Pharmaceutical Policy and Practice, the evaluation of analgesic utilization in public hospitals in China presented a rapid increase in the utilization of analgesics in China.
Furthermore, the utilization of NSAIDs and opioids showed a higher trend than other types of analgesics. The introduction of non-opioid analgesics in the country is expected to promote the sales of analgesics in China over the forecast period.
What is the Japan Analgesics Market Outlook?
Japan accounted for 31.8% of the East Asia analgesics market and is projected to expand at a CAGR of 4% from 2023 to 2033. There has been a swift trend favoring the demand aspect of analgesic utilization. Japan registered high sales of analgesics in 2018 and the demand was mostly concentrated in the older or geriatric population aiming to achieve a better quality of life.
Start-up Ecosystem: The Analgesics Market
Various acquisition strategies and product launches have been employed by new market players to increase their market presence.
- According to Novartis AG, it completed its acquisition of The Medical Company on January 06, 2020. With this acquisition, Novartis AG gained new opportunities for treating disability and preventing death through vaccines.
- Advil Dual Action was launched by GlaxoSmithKline PLC on September 10, 2020, and consists of two or more pain-relieving ingredients such as ibuprofen and acetaminophen. It helps to cure pain in two ways: Ibuprofen works through the body to target the source of pain, while acetaminophen blocks pain signals from reaching the brain.
Competitive Landscape
Some of the prominent players in the analgesics market are as follows:
- Pfizer Inc.
- Sun Pharmaceutical Industries, Inc.
- Sanofi SA
- AbbVie Inc. (Allergan plc)
- Teva Pharmaceuticals
- Boehringer Ingelheim International GmbH
- Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
- Endo Pharmaceuticals Inc.
- Purdue Pharmaceuticals L.P.
- Assertio Therapeutics, Inc.
- Mallinckrodt Pharmaceuticals
- Bayer AG
- GlaxoSmithKline plc.
- Bausch Health Companies Inc.
- Novartis AG
- Others
Recent Development: Large Scale Investment in R&D Activities for the Development of New Therapeutics
Key players are focusing on novel and innovative approaches for the development of non-opioid or non-addictive formulations for pain management. The strategy of expansion, new product launches, and approvals, by key manufacturers, is further strengthening their market presence.
- ZYNRELEF was launched in July 2021 by Heron Therapeutics Inc. Designed to provide postsurgical analgesia for up to 72 hours after a bunionectomy, inguinal herniorrhaphy, or total knee replacement, it is an extended-release product for soft tissue or periarticular application.
- In October 2017, Pfizer Inc., and other Leading health care organizations AmerisourceBergen, Blue Cross Blue Shield Association, and Prime Therapeutics are joining Walgreens (the nation's largest drugstore chains) to combat the national opioid abuse crisis by expanding the availability of safe medication disposal kiosks to an additional 900 Walgreens stores.
- In August 2018, Sun Pharma launched Volini Maxx, a pain relief spray.
Besides these, mergers and acquisitions have emerged as key growth strategies adopted by market players. Leading companies are strengthening their product portfolio and global footprint through acquisitions.
For instance:
- In May 2020, Assertio Therapeutics, Inc. merged with Zyla Life Sciences. The merger created a growing commercial pharmaceutical company with neurology, inflammation, and pain products.
Scope of Report
|
Attribute |
Details |
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2017-2022 |
|
Market Analysis |
US$ Mn for Value and MT for Volume |
|
Key Regions Covered |
|
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Chile, Peru, Germany, U.K., Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Turkey |
|
Key Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Analgesics Market Segmentation by Category
By Drug Class:
- Opioids
- NSAIDs
- Local Anesthetics
- Acetaminophen
By Indication:
- Surgical Pain
- Cancer Pain
- Neuropathic Pain
By Route of Administration:
- Oral
- Parenteral
- Transdermal
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- The Middle East and Africa
- East Asia
Frequently Asked Questions
The market size of the analgesics market in 2023 is US$ 87.3 Bn.
North America is a lucrative analgesics market and is expected to dominate throughout the forecast period.
The global market of analgesics is projected to reach a valuation of US$ 132.0 Bn by 2033.
The global market of analgesics is projected to grow at approximately a CAGR of 4.2%.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033
5.3.1. Opioids
5.3.2. NSAIDS
5.3.3. Local Anaesthetics
5.3.4. Acetaminophen
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023-2033
6. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Pain Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Pain Type, 2017-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Pain Type, 2023-2033
6.3.1. Surgical Pain
6.3.2. Cancer Pain
6.3.3. Neuropathic Pain
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Pain Type, 2017-2022
6.5. Absolute $ Opportunity Analysis By Pain Type, 2023-2033
7. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration , 2017-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration , 2023-2033
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Transdermal
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2017-2022
7.5. Absolute $ Opportunity Analysis By Route of Administration , 2023-2033
8. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2022
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Store
8.3.4. Clinics
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023-2033
9. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2022
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. APEJ
9.3.6. Japan
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Pain Type
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Pain Type
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Pain Type
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Pain Type
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2017-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. Italy
12.2.1.4. Spain
12.2.1.5. France
12.2.1.6. Benelux
12.2.1.7. Nordic
12.2.1.8. Rest of Western Europe
12.2.2. By Drug Class
12.2.3. By Pain Type
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Pain Type
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2017-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Rest of Eastern Europe
13.2.1.3. Russia
13.2.2. By Drug Class
13.2.3. By Pain Type
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Pain Type
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. APEJ Market Analysis 2017-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. Japan
14.2.1.2. Australia & New Zealand
14.2.1.3. China
14.2.1.4. India
14.2.1.5. Rest of APEJ
14.2.2. By Drug Class
14.2.3. By Pain Type
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Pain Type
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Japan Market Analysis 2017-2022 and Forecast 2023-2033, By Country
15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
15.2.1. By Country
15.2.2. By Drug Class
15.2.3. By Pain Type
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Pain Type
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2017-2022 and Forecast 2023-2033, By Country
16.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
16.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Pain Type
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Pain Type
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Pain Type
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Pain Type
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Pain Type
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Pain Type
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Pain Type
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Pain Type
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. Italy
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Pain Type
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Pain Type
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. France
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Pain Type
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. Benelux
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Pain Type
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Nordic
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Pain Type
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Poland
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Pain Type
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Russia
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Pain Type
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. Japan
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Pain Type
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Australia & New Zealand
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Pain Type
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. China
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Pain Type
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. India
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Pain Type
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. Japan
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Pain Type
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Pain Type
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Pain Type
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Pain Type
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Pfizer Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Sun Pharmaceutical Industries, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Sanofi SA
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. AbbVie Inc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Teva Pharmaceuticals
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Boehringer Ingelheim International GmbH
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Janssen Pharmaceuticals, Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Endo Pharmaceuticals Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Purdue Pharmaceuticals L.P.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Assertio Therapeutics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Mallinckrodt Pharmaceuticals
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Bayer AG
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. GlaxoSmithKline plc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Bausch Health Companies Inc.
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Novartis AG
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2033
Table 2: Global Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 3: Global Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 4: Global Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 5: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 6: North America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 7: North America Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 8: North America Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 9: North America Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 10: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 13: Latin America Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 14: Latin America Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 15: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 16: Western Europe Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 17: Western Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 18: Western Europe Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 19: Western Europe Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 20: Western Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 21: Eastern Europe Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 22: Eastern Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 23: Eastern Europe Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 24: Eastern Europe Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 25: Eastern Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 26: APEJ Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 27: APEJ Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 28: APEJ Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 29: APEJ Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 30: APEJ Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 31: Japan Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 32: Japan Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 33: Japan Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 34: Japan Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 35: Japan Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Table 36: MEA Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 37: MEA Market Value (US$ Mn) Forecast by Drug Class, 2017-2033
Table 38: MEA Market Value (US$ Mn) Forecast by Pain Type, 2017-2033
Table 39: MEA Market Value (US$ Mn) Forecast by Route of Administration , 2017-2033
Table 40: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 5: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2017-2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 9: Global Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 12: Global Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 15: Global Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 18: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 21: Global Market Attractiveness by Drug Class, 2023-2033
Figure 22: Global Market Attractiveness by Pain Type, 2023-2033
Figure 23: Global Market Attractiveness by Route of Administration , 2023-2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023-2033
Figure 25: Global Market Attractiveness by Region, 2023-2033
Figure 26: North America Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 27: North America Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 28: North America Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 29: North America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 30: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 37: North America Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 40: North America Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 43: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 46: North America Market Attractiveness by Drug Class, 2023-2033
Figure 47: North America Market Attractiveness by Pain Type, 2023-2033
Figure 48: North America Market Attractiveness by Route of Administration , 2023-2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023-2033
Figure 50: North America Market Attractiveness by Country, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 52: Latin America Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 53: Latin America Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 54: Latin America Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 55: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 59: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 62: Latin America Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 65: Latin America Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 68: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 71: Latin America Market Attractiveness by Drug Class, 2023-2033
Figure 72: Latin America Market Attractiveness by Pain Type, 2023-2033
Figure 73: Latin America Market Attractiveness by Route of Administration , 2023-2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023-2033
Figure 75: Latin America Market Attractiveness by Country, 2023-2033
Figure 76: Western Europe Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 77: Western Europe Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 78: Western Europe Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 79: Western Europe Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 80: Western Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 81: Western Europe Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 84: Western Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 87: Western Europe Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 90: Western Europe Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 93: Western Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 94: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 96: Western Europe Market Attractiveness by Drug Class, 2023-2033
Figure 97: Western Europe Market Attractiveness by Pain Type, 2023-2033
Figure 98: Western Europe Market Attractiveness by Route of Administration , 2023-2033
Figure 99: Western Europe Market Attractiveness by Distribution Channel, 2023-2033
Figure 100: Western Europe Market Attractiveness by Country, 2023-2033
Figure 101: Eastern Europe Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 102: Eastern Europe Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 103: Eastern Europe Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 104: Eastern Europe Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 105: Eastern Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 106: Eastern Europe Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 109: Eastern Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 112: Eastern Europe Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 115: Eastern Europe Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 118: Eastern Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 121: Eastern Europe Market Attractiveness by Drug Class, 2023-2033
Figure 122: Eastern Europe Market Attractiveness by Pain Type, 2023-2033
Figure 123: Eastern Europe Market Attractiveness by Route of Administration , 2023-2033
Figure 124: Eastern Europe Market Attractiveness by Distribution Channel, 2023-2033
Figure 125: Eastern Europe Market Attractiveness by Country, 2023-2033
Figure 126: APEJ Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 127: APEJ Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 128: APEJ Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 129: APEJ Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 130: APEJ Market Value (US$ Mn) by Country, 2023-2033
Figure 131: APEJ Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 132: APEJ Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 133: APEJ Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 134: APEJ Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 135: APEJ Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 136: APEJ Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 137: APEJ Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 138: APEJ Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 139: APEJ Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 140: APEJ Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 141: APEJ Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 142: APEJ Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 143: APEJ Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 144: APEJ Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 145: APEJ Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 146: APEJ Market Attractiveness by Drug Class, 2023-2033
Figure 147: APEJ Market Attractiveness by Pain Type, 2023-2033
Figure 148: APEJ Market Attractiveness by Route of Administration , 2023-2033
Figure 149: APEJ Market Attractiveness by Distribution Channel, 2023-2033
Figure 150: APEJ Market Attractiveness by Country, 2023-2033
Figure 151: Japan Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 152: Japan Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 153: Japan Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 154: Japan Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 155: Japan Market Value (US$ Mn) by Country, 2023-2033
Figure 156: Japan Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 157: Japan Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 158: Japan Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 159: Japan Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 160: Japan Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 161: Japan Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 162: Japan Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 163: Japan Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 164: Japan Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 165: Japan Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 166: Japan Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 167: Japan Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 168: Japan Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 169: Japan Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 170: Japan Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 171: Japan Market Attractiveness by Drug Class, 2023-2033
Figure 172: Japan Market Attractiveness by Pain Type, 2023-2033
Figure 173: Japan Market Attractiveness by Route of Administration , 2023-2033
Figure 174: Japan Market Attractiveness by Distribution Channel, 2023-2033
Figure 175: Japan Market Attractiveness by Country, 2023-2033
Figure 176: MEA Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 177: MEA Market Value (US$ Mn) by Pain Type, 2023-2033
Figure 178: MEA Market Value (US$ Mn) by Route of Administration , 2023-2033
Figure 179: MEA Market Value (US$ Mn) by Distribution Channel, 2023-2033
Figure 180: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 181: MEA Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 184: MEA Market Value (US$ Mn) Analysis by Drug Class, 2017-2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 187: MEA Market Value (US$ Mn) Analysis by Pain Type, 2017-2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Pain Type, 2023-2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Pain Type, 2023-2033
Figure 190: MEA Market Value (US$ Mn) Analysis by Route of Administration , 2017-2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by Route of Administration , 2023-2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Route of Administration , 2023-2033
Figure 193: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033
Figure 196: MEA Market Attractiveness by Drug Class, 2023-2033
Figure 197: MEA Market Attractiveness by Pain Type, 2023-2033
Figure 198: MEA Market Attractiveness by Route of Administration , 2023-2033
Figure 199: MEA Market Attractiveness by Distribution Channel, 2023-2033
Figure 200: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
